Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-25
2010-02-23
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07666881
ABSTRACT:
The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulaswhich are useful as antihistamines, antiallergic agents and bronchodilators.
REFERENCES:
patent: 3965257 (1976-06-01), Carr
patent: 4254129 (1981-03-01), Carr et al.
patent: 5204249 (1993-04-01), Schwartz
patent: 5375693 (1994-12-01), Woosley et al.
patent: 5574045 (1996-11-01), Ortyl et al.
patent: 5578610 (1996-11-01), D'Ambra
patent: 5631375 (1997-05-01), King et al.
patent: 5738872 (1998-04-01), Ortyl et al.
patent: 5855912 (1999-01-01), Ortyl et al.
patent: 5932247 (1999-08-01), Ortyl et al.
patent: 6037353 (2000-03-01), Woodward et al.
patent: 6039974 (2000-03-01), MacLaren et al.
patent: 6113942 (2000-09-01), Ortyl et al.
patent: 6147216 (2000-11-01), Krauss
patent: 6187791 (2001-02-01), Woodward et al.
patent: 6242606 (2001-06-01), Krauss
patent: 6399632 (2002-06-01), Woodward et al.
patent: 6613906 (2003-09-01), Davies et al.
patent: 7135571 (2006-11-01), Henton et al.
patent: 1123438 (1982-05-01), None
patent: 1123439 (1982-05-01), None
patent: 2117892 (1993-10-01), None
patent: 2181089 (1994-12-01), None
patent: 117237 (2001-01-01), None
patent: 134917 (2001-07-01), None
patent: 134771 (2002-02-01), None
patent: WO 94/03170 (1994-02-01), None
patent: WO 94/09008 (1994-04-01), None
patent: WO 95/00480 (1995-01-01), None
Rowland and Tozer “Clinical pharmacokinetics concepts and application” p. 123 (1995).
Gibson et al. “Modulation of antagonisti binding. . . ” Br. J. Pharmcol. v. 111 (Apr.) p. 1262-1268 (1994).
Muzaffar et al. “Polymorphism and drug availability” J. Phar. 1(1) 59-66 (1979).
Jain et al. “Polymorphisom in pharmacey” Indian Drugs 23(g)315-329 (1986).
Doelker et al. “Crystalline modification . . . ” CA 138:209993 (2002).
Doelker et al. “Physicochemical behavior or active . . . ” CA 132:325872 (2000).
Otsuka et al. “Effect of polymorphic . . . ” Chem. Pharm. bull 47(6)852-856 (1999).
Copies in parent case.
Glusker et al. “Crystal structure analysis a primer” p. 12 (1985).
Ochai “In re Ochiai 37 USPQ2d 1127” (1995).
SmKI Apotex “SmithKline v Apotex 74 USPQ2d 1398” (2005).
Copending claims as of Oct. 30, 2007, for related U.S. Appl. No. 11/534,839.
Copending claims as of Oct. 26, 2006, for related U.S. Appl. No. 11/553,751.
Copending claims as of Oct. 30, 2007, for related U.S. Appl. No. 11/978,669.
Copending claims as of Oct. 30, 2007, for related U.S. Appl. No. 11/978,670.
Affidavit of Lilach Goldman, dated Jul. 10, 2006.
Akaishi et al., “Synthesis of Diamond Using Nonmetallic Catalysts,” Chem. Abstracts 116:73144 (1992).
Amon, U. et al. “Anti-allergic effects of H1-receptor antagonists on histamin-containing cells,”Dermatologische Monatsschrift(1992) 178(8):327-33.
Applicant's Reply to Respondent's Response to the Application for Interlocutory Remedies, C.F. 1088/06 (Israel Patent No. 134,917) and English-language translation.
Bailey, D. G. et al. “Effect of Grapefruit Juice and Naringin on Nisoldipine Pharmacokinetics,”Clinical Pharmacology&Therapeutics(1993) 54(6):589-94.
Bailey, D. G. et al. “Grapefruit Juice—Felodipine Interaction: Mechanism, Predictability, and Effect of Naringin”Clinical Pharmacology&Therapeutics(1993) 53:637-42.
Bailey, D. G. et al. “Grapefruit Juice—Felodipine Interaction: Reproducibility and Characterization with the Extended Release Drug Formulation,”Br. J. Clinical Pharmacology(1995) 40:135-40.
Bailey, D. G. et al. “Grapefruit Juice and Drugs: How Significant is the Interaction,”Clinical Pharmacokinetics(1994) 26(2):91-98.
Baroody, F. et al. “The Effects of H1antihistamines on the Early Allergic Response,”Annals of Allergy(1989) 63:551-55.
Bennett et al. “Concise chemical and technical dictionary”Chem. Pub.(1976) p. 553.
Cantilena, L. et al. “Effect of Cimetidine and Ranitidine on the Pharmacokinetics and ECG Pharmacodynamics of Terfenadine,”Clinical Pharmacology&Therapeutics(1993) 53(2):161.
Chan, K. Y. et al. “Direct Enantiomerica Separation of Terfenadine and Its Major Acid Metabolite by High-Performance Liquid Chromatography, and the Lack of Stereoselective Terfenadine Enantiomer Biotransformation in Man,” CA 116:50726 (1992).
Chan, K. Y. et al. “Direct Enantiomeric Separation of Terfenadine and its Major Acid Metabolite by High-Performance Liquid Chromatography, and the Lack of Stereoselective Terfenadine Enantiomer Biotransformation in Man,”J. Chromatography(1991) 571:291-97.
Charlesworth, E. N. et al. “Cutaneous Late-Phase Response in Food-Allergic Children and Adolescents with Atopic Dermatitis,”Clinical and Experimental Allergy(1993) 23:391-98.
Chen, T.-M. et al. “Determination of the Metabolites of Terfenadine in Human Urine by Thermospray Liquid Chromatography—Mass Spectrometry,”J. Pharmaceutical and Biomedical Analysis(1991) 9(10-12):929-33.
Cheronis, N. D.Semimicro Experimental Organic Chemistry, A Laboratory Manual8 (J de Graft 1958).
Cheronis, N. D.Semimicro Experimental Organic Chemistry, A Laboratory Manual16-17 (J de Graff 1958).
Argentine Search Report in Application No. 332047, dated Sep. 13, 1999.
Canadian Office Action in Application No. 2,189,007, dated Nov. 6, 1998.
European Search Report in European Application No. 01124314.4-2101, dated Dec. 20, 2001.
Norwegian Search Report in Application No. 1996 4859, dated Nov. 21, 2001.
PCT International Search Report in Application No. PCT/US95/04942, dated Aug. 10, 1995.
Coutant, J. E. et al. “Determination of Terfenadine and Terfenadine Acid Metabolite in Plasma Using Solid-Phase Extraction and High-Performance Liquid Chromatography with Flourescence Detection, ”J. Chromatography(1991) 570:139-48.
Crumb, W. J. et al. “Blockade of Multiple Human Cardiac Potassium Currents by the Antihistamine Terfenadine: Possible Mechanism for Terfenadine-Associated Cardiotoxicity,”Molecular Pharmacology(1995) 47:181-90.
Dean, J. A., “Analytical Chemistry Handbook,” 10.24 (McGraw Hill 1995).
Declaration David E. Bugay, Ph.D., dated Mar. 22, 2006.
Declaration of David E. Bugay, Ph.D., dated Apr. 2, 2006, and Exhibits A-E.
Declaration of Dr. Alan P. Kozikowsky, signed Jul. 7, 2006, and submitted in Israeli litigation, with exhibits A-M.
Declaration of Dr. Marcus F. Brackeen, signed Jul. 7, 2006, and submitted in Israeli litigation, with exhibits A-F.
Declaration of Dr. Mark D. Hollingsworth, signed Jul. 6, 2006, and submitted in Israeli litigation, with exhibits A-E.
Declaration of Dr. William E. Mayo, signed Jul. 7, 2006, and submitted in Israeli litigation, with exhibits A-M.
Declaration of Prof. Abraham Rubinstein, signed Jul. 9, 2006, and submitted in Israeli litigation, with exhibits A-C, including English-language Translation of Appendix B.
Declaration of Prof. Clare Grey, signed Jul. 7, 2006, and submitted in Israeli litigation, with exhibits A-F.
Declaration of Prof. Joel Bernstein, dated Apr. 2, 2006.
Declaration of Prof. Joel Bernstein, dated Mar. 22, 2006.
Declaration of Prof. Peter W. Stephens, signed Jul. 7, 2006, and submitted in Israeli litigation.
Distinction between Crystalline and Amorphous Solids, Encyclopedia Britannica Online (2004).
Eagleson, M. “Concise Encyclopedia Chemistry,” 872-873 (1944).
English-Language Translation of Affidavit of Dr. Shmuel Cohen.
English-Language Translation of Affidavit of Hagit Saban.
English-language Translation of Affidavit of Lilach Goldman, dated Jul. 10, 2006.
English-Language Translation of Affidavit of Mike Netz.
English-Language Translation of Affidavit of Netanel Aharonov.
English-Language Translation of Affidavit of Prof. Abraham Rubinstein.
English-Language Translation of Nov. 1, 2005, Letter from Israeli Patent Office to Seligsohn Gabrielli
DeWitt Jill E.
Henton Daniel R.
McCarty Frederick J.
Tripp Susan I.
Aventis Holdings, Inc.
Chang Celia
O'Brien Jones PLLC
LandOfFree
Methods of treating allergic reactions using hydrated forms... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating allergic reactions using hydrated forms..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating allergic reactions using hydrated forms... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183867